A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

por Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Hellmann, Andrzej, Taussig, David C., Tormo, Mar, Voso, Maria Teresa, Cavenagh, James, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Silverman, Lewis R.
Publicado 2022

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

por Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Ogasawara, Ken, Cavenagh, James, Silverman, Lewis R., Voso, Maria Teresa, Hellmann, Andrzej, Tormo, Mar, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Garcia-Manero, Guillermo
Publicado 2022